Trial Profile
A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs Bupropion/dextromethorphan (Primary) ; Bupropion
- Indications Agitation
- Focus Registrational; Therapeutic Use
- Acronyms ADvance; ADVANCE-1
- Sponsors Axsome Therapeutics
- 03 Nov 2020 According to an Axsome Therapeutics media release, data from this study will be presented at the in an oral session at the 13th Clinical Trials on Alzheimer Disease (CTAD) conference, to be held digitally, November 4-7.
- 31 Jul 2020 Status changed to completed.
- 31 Jul 2020 Results presented at the Alzheimer's Association International Conference 2020.